[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100562516":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":22,"locations":21,"responsibleParty":32,"collaborators":34,"id":37,"slug":38,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":21,"eligibilityCriteria":43,"healthyVolunteers":44,"sex":45,"minAge":46,"maxAge":47,"enrollmentInfo":48,"targetDuration":21,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":21,"overallStatus":57,"whyStopped":21,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":21},{"fullName":5,"class":6},"Frontline AIDS","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"HCV positive","EXPERIMENTAL","Eligible participants that are HCV infected.",[13],"Other: Community-based Simplified HCV Testing and Treatment Algorithm",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"Community-based Simplified HCV Testing and Treatment Algorithm","The distinctive features of CBSA are: (i) community-based service provision, substantially lowering the threshold for HCV services and eliminating the need to visit health care facilities for the majority of patients; (ii) the use of simple, once-daily, pan-genotypic HCV treatment regimens; (iii) a minimum of required laboratory tests and assessments; (iv) task sharing of essential functions from physicians to the case-managers; (v) integration of HCV testing and treatment with existing harm reduction services, addressing multiple health needs and facilitating patient-centered care.",[9],[20],"CBSA",null,[23,28],{"name":24,"role":25,"phone":26,"phoneExt":21,"email":27},"Anna Meteliuk, PhD","CONTACT","+380988220510","meteliuk@aph.org.ua",{"name":29,"role":25,"phone":30,"phoneExt":21,"email":31},"Abraham J Olivier, PhD","+447775912022","colivier@frontlineaids.org",{"type":33,"investigatorFullName":21,"investigatorTitle":21,"investigatorAffiliation":21,"oldNameTitle":21,"oldOrganization":21},"SPONSOR",[35],{"name":36,"class":6},"Alliance for the Public's Health","100562516","innovate-involve-inspire-100562516",false,"NCT06604182","Innovate, Involve, Inspire","Community-based HCV Testing and Treatment of People Who Inject Drugs: Innovate, Involve, Inspire","Inclusion Criteria:\n\n* Drug use in the past 90 days\n* Age 18 and above\n* Positive for HCV RNA\n\nExclusion Criteria:\n\n* No meeting inclusion criteria\n* Pregnancy",true,"ALL","18 Years","60 Years",{"count":49,"type":50},1454,"ESTIMATED","INTERVENTIONAL",[53],"NA","The study will test a Community-based Simplified HCV Testing and Treatment Algorithm (CBSA), implemented at community harm reduction fixed or mobile sites.\n\nAll potential participants with positive anti-HCV test will undergo diagnostic procedures including HCV-RNA testing. Those eligible for CBSA will be prescribed a fixed dose combination tablet: sofosbuvir\u002Fdaclatasvir.\n\nSustained virologic response (SVR) will be assessed 12 weeks after treatment completion. All those who achieve SVR will be tested for HCV\\_RNA at six and 12 months after SVR12.",[56],"HCV","NOT_YET_RECRUITING","2024-09-17",{"date":60,"type":61},"2024-09-19","ACTUAL",{"date":63,"type":50},"2025-01",{"date":65,"type":50},"2026-07",{"name":5,"class":6}]